IT Solutions
Limited access to data 'could increase potential of science software'
Jan 07 2011
Researchers at the University of Southern California (USC) looked into how restricted access to previous findings for use in modern science software can impact on production costs and time to market.
Perhaps intuitively, they found costs are increased when previous research findings are made less available to those working on new pharmaceutical and clinical solutions.
However, they claim that life expectancy would increase and more products would be developed if tighter restrictions were imposed on data.
By extending controls in the US from the current standard period of five years to that used in Europe, which is around ten years, the scientists claim generic drug manufacturers could be dissuaded from focusing on cheaper versions of existing therapies.
This, they say, would increase costs but also drive innovation of entirely new solutions, rather than cheaper duplication of existing drugs.
USC claims to be a leader in an "ever-flattening world" thanks to its high proportion of international students compared with other US academic institutions.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia